open access
Vol 72, No 2 (2021)
Editorial
Submitted: 2021-02-07
Accepted: 2021-02-09
Published online: 2021-04-30
Get Citation
Adjuvant therapy in type 1 diabetes mellitus — choice or necessity in the COVID-19 pandemic?
1
Affiliations- Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Medical University of Silesia, Katowice, Poland
open access
Vol 72, No 2 (2021)
Editorial
Submitted: 2021-02-07
Accepted: 2021-02-09
Published online: 2021-04-30
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Adjuvant therapy in type 1 diabetes mellitus — choice or necessity in the COVID-19 pandemic?
Journal
Issue
Article type
Editorial
Pages
89-90
Published online
2021-04-30
Page views
916
Article views/downloads
743
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2021;72(2):89-90.
Authors
Edyta Cichocka
References (14)- Cichocka E, Maj-Podsiadło A, Gumprecht J. Adjuvant therapy in type 1 diabetes mellitus. Endokrynol Pol. 2021; Ahead of Print.
- Al Khalifah RA, Alnhdi A, Alghar H, et al. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis. Pediatr Diabetes. 2017; 18(7): 664–673.
- Libman IM, Miller KM, DiMeglio LA, et al. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2015; 314(21): 2241–2250.
- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774–800.
- Escobar-Morreale HF, Roldán-Martín MB, Escobar-Morreale HF, et al. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016; 39(4): 639–648.
- Milewicz A, Kudła M, Spaczyński RZ, et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018; 69(4).
- Casu A, Bilal A, Pratley RE, et al. Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON). Pharmacological therapies to address obesity in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2020; 27(4): 194–206.
- Maj-Podsiadło A, Cichocka E, Gumprecht J, et al. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes. Clin Diab. 2020; 9(3): 189–192.
- Huang Y, Jiang Z, Wei Y, et al. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis. Endokrynol Pol. 2020; 71(4): 325–333.
- Yamada T, Shojima N, Noma H, et al. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018; 20(7): 1755–1761.
- Danne T, Cariou B, Buse JB, et al. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019; 42(5): 919–930.
- Danne T, Garg S, Peters AL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019; 42(6): 1147–1154.
- Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016; 4(3): 221–232.
- Mathieu C, Zinman B, Hemmingsson JU, et al. ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016; 39(10): 1702–1710.
